First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors

Journal of Clinical Oncology

Volumn 34, Issue 34, 2016, Pages 4142-4150

  Abdul Razak, Albiruni R ^a   Mau Soerensen, Morten ^b   Gabrail, Nashat Y ^c   Gerecitano, John F ^d   Shields, Anthony F ^e   Unger, Thaddeus J ^f   Saint Martin, Jean R ^f   Carlson, Robert ^f   Landesman, Yosef ^f   McCauley, Dilara ^f   Rashal, Tami ^f   Lassen, Ulrik ^b   Kim, Richard ^g   Stayner, Lee Anne ^a   Mirza, Mansoor R ^f   Kauffman, Michael ^f   Shacham, Sharon ^f   Mahipal, Amit ^g  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b University of Copenhagen   (Denmark)

^c Gabrail Cancer Center   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e WAYNE STATE UNIVERSITY   (United States)

^f Karyopharm Therapeutics Inc   (United States)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ANTIEMETIC AGENT; CORTICOSTEROID; EXPORTIN 1; GLUTATHIONE; MEGESTROL ACETATE; MESSENGER RNA; OLANZAPINE; PARACETAMOL; SELINEXOR; TRIACYLGLYCEROL LIPASE; TUMOR SUPPRESSOR PROTEIN; HYDRAZINE DERIVATIVE; KPT-330; TRIAZOLE DERIVATIVE;

ADRENAL CORTEX TUMOR; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANUS CANCER; APOPTOSIS; APPENDIX CANCER; ARTICLE; ATAXIA; BLADDER CANCER; BLURRED VISION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER PATIENT; CATARACT; CELL PROLIFERATION; CEREBELLUM DISEASE; CHORDOMA; CLINICAL EVALUATION; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEHYDRATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSARTHRIA; DYSGEUSIA; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FIRST IN HUMAN STUDY; GERM CELL TUMOR; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; KIDNEY FAILURE; LEUKOCYTE; LEUKOPENIA; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG CANCER; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MEDICATION COMPLIANCE; MELANOMA; MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ORAL BLEEDING; OVARY CANCER; PANCREAS CANCER; PANCREATITIS; PATIENT COMPLIANCE; PRESYNCOPE; PRIORITY JOURNAL; PROPHYLAXIS; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA; SIDE EFFECT; SMALL INTESTINE CANCER; SOLID TUMOR; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR BIOPSY; UROGENITAL TRACT CANCER; UTERINE CERVIX CANCER; VOMITING; VULVA CANCER; WEIGHT REDUCTION; XEROSTOMIA; BIOPSY; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; METHODOLOGY; MIDDLE AGED; NEOPLASMS; NUCLEOCYTOPLASMIC TRANSPORT; PATHOLOGY; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME; VERY ELDERLY;

ACTIVE TRANSPORT, CELL NUCLEUS; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDRAZINES; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASMS; RESEARCH DESIGN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TRIAZOLES;

EID: 84995975390     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.3949     Document Type: Article

References (35)

1. Zaidi SK, Young DW, Javed A, et al: Nuclear microenvironments in biological control and cancer. Nat Rev Cancer 7:454-463, 2007
2. Turner JG, Dawson J, Sullivan DM: Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 83:1021-1032, 2012
3. Cook A, Bono F, Jinek M, et al: Structural biology of nucleocytoplasmic transport. Annu Rev Biochem 76:647-671, 2007
4. Kau TR, Way JC, Silver PA: Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer 4:106-117, 2004
5. Turner JG, Marchion DC, Dawson JL, et al: Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Res 69:6899-6905, 2009
6. Huang WY, Yue L, Qiu WS, et al: Prognostic value of CRM1 in pancreas cancer. Clin Invest Med 32:E315, 2009
7. Lesinski GB, Yang J, Bill MA, et al: Effect of small inhibitors of nuclear export (SINE) on growth inhibition and apoptosis of human melanoma cells. J Clin Oncol 30, 2012 (suppl; abstr e13549)
8. Noske A, Weichert W, Niesporek S, et al: Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer 112:1733-1743, 2008
9. Shen A, Wang Y, Zhao Y, et al: Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery 65: 153-159, 2009
10. van der Watt PJ, Maske CP, Hendricks DT, et al: The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer 124:1829-1840, 2009
11. van der Watt PJ, Leaner VD: The nuclear exporter, Crm1, is regulated by NFY and Sp1 in cancer cells and repressed by p53 in response to DNA damage. Biochim Biophys Acta 1809:316-326, 2011
12. Yao Y, Dong Y, Lin F, et al: The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep 21:229-235, 2009
13. Tan DS, Bedard PL, Kuruvilla J, et al: Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy. Cancer Discov 4:527-537, 2014
14. Azmi AS, Kauffman M, McCauley D, et al: Novel small-molecule CRM-1 inhibitor for GI cancer therapy. J Clin Oncol 30, 2012 (suppl 4; abstr 245)
15. Chung HW, Salas Fragomeni RA, Shacham S, et al: Effect of inhibition of nuclear protein export using a novel CRM1 inhibitor on the apoptotic response to SN38 in preclinical colon cancer models. J Clin Oncol 30, 2012 (suppl 4; abstr 609)
16. Inoue H, Kauffman M, Shacham S, et al: Evaluation of selective inhibitors of nuclear export (SINE) CRM1 inhibitors for the treatment of renal cell carcinoma (RCC). J Clin Oncol 30, 2012 (suppl; abstr 4634)
17. Lapalombella R, Sun Q, Williams K, et al: Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 120:4621-4634, 2012
18. McCauley D, Landesman Y, Senapedis W, et al: Preclinical evaluation of selective inhibitors of nuclear export (SINE) in basal-like breast cancer (BLBC). J Clin Oncol 30, 2012 (suppl; abstr 1055)
19. Shacham S, Kauffman M, Sandanayaka V, et al: Preclinical development of small-molecule CRM1 inhibitors as novel therapy for the treatment of colorectal cancer (CRC). J Clin Oncol 29, 2011 (suppl 4; abstr 430)
20. Green AL, Ramkissoon SH, McCauley D, et al: Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma. Neuro Oncol 17:697-707, 2015
21. Chen Y, Kalir E, Camacho-Venegas C, et al: Increased overall survival in platinum-resistant ovarian cancer: paradigmatic use of novel SINE (selective inhibitor of nuclear export), which restores p53 nuclear localization and activation. Cancer Res 73:2163, 2013 (abstr)
22. Parikh K, Cang S, Sekhri A, et al: Selective inhibitors of nuclear export (SINE): A novel class of anti-cancer agents. J Hematol Oncol 7:78, 2014
23. Mahaseth H, Maity S, Gabrail N, et al: Selinexor (KPT-330), an oral, selective inhibitor of nuclear export (SINE) shows anti-prostate cancer (PrCa) activity preclinically and disease control in patients (pts) with chemotherapy refractory, castrate-resistant prostate cancer (CRPC). Ann Oncol 25, 2014 (suppl 4; abstr iv257)
24. Etchin J, Sun Q, Kentsis A, et al: Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia 27:66-74, 2013
25. Shacham S, Barnard S, Kisseberth W, et al: Results of a phase I dose escalation study of the novel, oral CRM1 selective inhibitor of nuclear export (SINE) KPT-335 in dogs with spontaneous non-Hodgkin's lymphomas (NHL). Blood 120:161, 2012 (abstr)
26. National Cancer Institute: Common Terminology Criteria for Adverse Events v4.03. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11.pdf
27. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
28. Newlands ES, Rustin GJ, Brampton MH: Phase I trial of elactocin. Br J Cancer 74:648-649, 1996
29. Martingnetti J, Razak A, Chen Y, et al: Preclinical and early clinical activity of the oral selective inhibitor of nuclear export (SINETM) exportin 1 (XPO1) antagonist selinexor (KPT-330) in patients with platinum resistant/refractory ovarian cancer (OvCa). Ann Oncol 25, 2014 (suppl 4; abstr iv310)
30. Kazim S, Malafa MP, Coppola D, et al: Selective nuclear export inhibitor KPT-330 enhances the antitumor activity of gemcitabine in human pancreatic cancer. Mol Cancer Ther 14:1570-1581, 2015
31. Salas Fragomeni RA, Chung HW, Landesman Y, et al: CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma. Mol Cancer Ther 12:1171-1179, 2013
32. Miyake TM, Pradeep S, Zand B, et al: Therapeutic targeting of CRM1 in ovarian cancer. Cancer Res 73:5541, 2013
33. Chung HW, Salas Fragomeni RA, Shacham S, et al: Use of selective inhibition of nuclear export (SINE) using a CRM1/XPO1 antagonist to overcome resistance to CPT-11 in colon cancer in preclinical models. J Clin Oncol 31, 2013 (suppl 4; abstr 396)
34. Miyake T, Pradeep S, Wu SY, et al: XPO1/CRM1 inhibition causes antitumor effects by mitochondrial accumulation of eIF5A. Clin Cancer Res 21:3286-3297, 2015
35. Rashal T, Elloul S, Crochiere M, et al: Selinexor (KPT-330) radio-sensitizes non-small cell lung cancer cells in vitro and in vivo. Cancer Res 75:4490, 2015 (abstr)